InflaRx N.V.’s $100 million initial public offering on the NASDAQ Global Select Market,

Loyens & Loeff acted as Dutch corporate counsel to the underwriters with respect to the IPO of InflaRx N.V. on the NASDAQ Global Select Market, under the ticker symbol IFRX.

German biopharmaceutical InflaRx, which is developing therapeutics for rare inflammatory diseases, completed a $100 million initial public offering on the Nasdaq Global Select Market.

InflaRx sold just under 6.7 million shares at $15 per share, the mid-point of its expected range. InflaRx is trading under the ticker IFRX. The share rose to a high of $15.48 in their trading debut, but ended the day at $14.99, down 1 cent.

InflaRx’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases. The complement system is part of the immune system and defends against infection.

J.P. Morgan, Leerink Partners and BMO Capital Markets are acting as joint book-running managers for the offering.

Loyens & Loeff advised the underwriters on the deal with a team led by Gerco van Eck (picture) and Martijn Schoonewille.

Involved fees earner: Gerco van Eck – Loyens & Loeff; Martijn Schoonewille – Loyens & Loeff;

Law Firms: Loyens & Loeff;

Clients: JP Morgan; Leerink Partners; BMO Capital Markets;